Find a Therapeutic By Name

Search By Attributes

Therapy Type

Combination
DNA/RNA-based
Immunotherapy (active)
Immunotherapy (passive)
Other
Procedural Intervention
Small Molecule
Supplement, Dietary

Condition

Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Cerebral Amyloid Angiopathy
Frontotemporal Dementia
Mild Cognitive Impairment
Parkinson's Disease

Keyword

2 Therapeutics

Search Results

Name	Synonyms	FDA Status	Company	Target Type	Therapy Type	Approved For
AL101	GSK-4527226	Alzheimer's Disease (Phase 2)	Alector, GlaxoSmithKline (GSK)	Other	Immunotherapy (passive)
Latozinemab	AL001, GSK4527223	Frontotemporal Dementia (Phase 3), Amyotrophic Lateral Sclerosis (Inactive)	Alector, GlaxoSmithKline (GSK)	Other	Immunotherapy (passive)